Compare · KIDS vs WST
KIDS vs WST
Side-by-side comparison of OrthoPediatrics Corp. (KIDS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KIDS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.22B, about 47.2x KIDS ($470.5M).
- Over the past year, KIDS is down 14.8% and WST is up 42.9% - WST leads by 57.7 points.
- WST has been more active in the news (4 items in the past 4 weeks vs 2 for KIDS).
- WST has more recent analyst coverage (16 ratings vs 8 for KIDS).
- Company
- OrthoPediatrics Corp.
- West Pharmaceutical Services Inc.
- Price
- $18.33+0.22%
- $319.83+1.72%
- Market cap
- $470.5M
- $22.22B
- 1M return
- +4.56%
- -0.66%
- 1Y return
- -14.82%
- +42.89%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 2
- 4
- Recent ratings
- 8
- 16
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest KIDS
- OrthoPediatrics Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- OrthoPediatrics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- General Counsel and Secretary Gerritzen Daniel J gifted 2,479 shares, decreasing direct ownership by 2% to 147,054 units (SEC Form 4)
- SEC Form 10-Q filed by OrthoPediatrics Corp.
- OrthoPediatrics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- OrthoPediatrics Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance
- OrthoPediatrics Expands Specialty Bracing Portfolio with TRAXIO Halo Gravity Traction System
- SEC Form DEF 14A filed by OrthoPediatrics Corp.
- SEC Form DEFA14A filed by OrthoPediatrics Corp.
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)